ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $28.25 Consensus Target Price from Analysts

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has received a consensus recommendation of “Hold” from the five research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $28.25.

SPRY has been the topic of a number of research analyst reports. Weiss Ratings lowered ARS Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Northland Securities initiated coverage on ARS Pharmaceuticals in a research note on Thursday, April 9th. They set an “outperform” rating and a $25.00 price target on the stock. Leerink Partners set a $26.00 price target on ARS Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Finally, Zacks Research upgraded ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th.

ARS Pharmaceuticals Price Performance

Shares of SPRY stock opened at $8.74 on Monday. ARS Pharmaceuticals has a fifty-two week low of $6.66 and a fifty-two week high of $18.90. The firm has a market capitalization of $867.88 million, a price-to-earnings ratio of -4.99 and a beta of 0.93. The company has a debt-to-equity ratio of 1.47, a quick ratio of 7.06 and a current ratio of 7.28. The stock’s 50-day simple moving average is $8.41 and its 200-day simple moving average is $9.35.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.42) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.42). ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%.The business had revenue of $28.09 million for the quarter, compared to analyst estimates of $25.58 million. As a group, equities analysts forecast that ARS Pharmaceuticals will post -1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ARS Pharmaceuticals

Large investors have recently bought and sold shares of the company. CWM LLC boosted its position in ARS Pharmaceuticals by 243.7% in the third quarter. CWM LLC now owns 2,547 shares of the company’s stock valued at $26,000 after buying an additional 1,806 shares during the last quarter. Torren Management LLC purchased a new stake in ARS Pharmaceuticals in the fourth quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. boosted its position in ARS Pharmaceuticals by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after buying an additional 982 shares during the last quarter. Bessemer Group Inc. boosted its position in ARS Pharmaceuticals by 3,102.1% in the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock valued at $61,000 after buying an additional 7,290 shares during the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in ARS Pharmaceuticals in the fourth quarter valued at approximately $65,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.